Ferrer, a pharmaceutical company and CataloniaBio & HealthTech member, has been granted a €50 million loan from the European Investment Bank (EIB) to develop innovative new treatments in pulmonology and neurology.

The R&D programme the company presented will run through 2024. Currently, Ferrer’s R&D activity is broken down into the Ferrer Advanced Biotherapeutics (FAB), Ferrer Innovation Management (FIM), and digital health and technology divisions.The deal with the EIB reinforces Ferrer’s financial solidity and complements a €220-million funding agreement reached in 2020 with several financial institutions.

More information

Photo: Mario Rovirosa, CEO of Ferrer.

You may also be interested in:

• Indian start-up Wellthy Therapeutics wins Ferrer 4 Future
  
• The second edition of Ferrer 4 Future is underway